Last reviewed · How we verify
NCT07265349
A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure
Phase 1, PHASE2 trial testing Mesenchymal stem cells(HucMSCs) in Coronary Artery Bypass Grafting (CABG) in 51 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Tasly Pharmaceutical Group Co., Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 26 December 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 1 August 2027 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Mesenchymal stem cells(HucMSCs) — full drug profile →
- CABG
Conditions studied
- Coronary Artery Bypass Grafting (CABG) — all drugs for Coronary Artery Bypass Grafting (CABG) →
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
- Chronic Ischemic Cardiomyopathy — all drugs for Chronic Ischemic Cardiomyopathy →
Sponsor
Tasly Pharmaceutical Group Co., Ltd — full company profile →
Who can join
Adults 18 to 80, any sex, with Coronary Artery Bypass Grafting (CABG) or Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
B2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated that the B2278 injection promote the polarization of macrophages towards a reparative state through paracrine action, directly promote angiogenesis and inhibited inflammatory responses, thereby exerting effects on myocardial repair and treatment of heart failure, and it is also safe and well-tolerated. This trial is a multi-center I/II phase clinical trial of the human umbilical cord mesenchymal stem cell injection solution, aiming to explore the dosage and regimen for the intramyocardial injection of B2278 in combination with coronary artery bypass grafting surgery for the treatment of chronic heart failure caused by chronic ischemic cardiomyopathy, and to evaluate the safety, tolerance and efficacy of allogeneic intramyocardial injection of the human umbilical cord mesenchymal stem cell injection solution in patients with chronic ischemic heart failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07265349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Bypass Grafting (CABG)
Currently open trials in the same condition.
- NCT06586749 — Effect of Nurse-Led Education and Tele-Interventions on Reducing Surgical Site Infections in Patients After Coronary Art · NA · recruiting
- NCT07034586 — Prospective Evaluation of Adventitial Histopathology in Borderline Ascending Aortic Dilatatio · active not recruiting
Other Tasly Pharmaceutical Group Co., Ltd trials
Trials by the same sponsor.
- NCT07269769 — A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD · Phase 3 · not yet recruiting
- NCT07485595 — A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe Depression · Phase 2, PHASE3 · not yet recruiting
- NCT07514065 — TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy · Phase 1 · recruiting
- NCT07318818 — A Clinical Trial of P134 Cells in Recurrent Glioblastoma · Phase 1, PHASE2 · recruiting
- NCT06773117 — Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07265349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tasly Pharmaceutical Group Co., Ltd
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07265349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing